CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell TherapiesJesse Green, Terry J. Fry, Adam Johnson et al.|Blood|2022Cited by 5
Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell TherapyAdam Johnson, Terry J. Fry, Jeremy M. Kinder et al.|Blood|2023Cited by 4
Preclinical Efficacy of a Novel CD8-Targeted Fusosome for In Vivo CAR T Cell TherapyVandana Chaturvedi, Terry J. Fry, Jesse Green et al.|Blood|2023Cited by 3
Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma PatientsJeremy M. Kinder, Terry J. Fry, Chanel Athena Estrada et al.|Blood|2023Cited by 3
A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen EscapeAdam Johnson, Aaron E. Foster, Hallee Wright et al.|Blood|2022Cited by 2